[Changes the level of differentiating growth factor - GDF 15 in patients with sleep apnea syndrome after aPAP-therapy: pilot study].

Irina M Madaeva E V Titova Olga N Berdina L F Sholokhov Sergey Kolesnikov Lyubov I Kolesnikova

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)

A 6-month course of aPAP therapy made it possible to eliminate intermittent nocturnal hypoxia and improve sleep structure in patients with OSA, as well as reduce the content of GDF 15 protein in blood serum in patients with OSA. However, the tendency to decrease the content of this protein, despite the lack of statistical reliability, confirms the effectiveness of OSA therapy and the possibility of preventing early and pathological aging from the standpoint of somnology and molecular biogerontology.

Keyphrases

obstructive sleep apnea
sleep apnea
growth factor
positive airway pressure
randomized controlled trial
systematic review
physical activity
magnetic resonance
magnetic resonance imaging
protein protein
small molecule
endothelial cells
high intensity
depressive symptoms
single molecule
smoking cessation